A foreign pharmaceutical manufacturer cannot hold a Malaysian product registration directly. You need a locally incorporated Marketing Authorisation Holder (MAH), an import licence and GDP-compliant distribution. If your product is already approved by a recognised agency - EMA, US FDA, Swissmedic, UK MHRA, Health Canada, PMDA or TGA - NPRA's reliance routes can shorten the review, and an EMA or FDA approval can qualify for a 60-working-day pilot route that started on 2 May 2026.
A note on terms: NPRA officially calls the holder the Product Registration Holder (PRH). Throughout RHMI's guides we use the equivalent international term, Marketing Authorisation Holder (MAH) - they mean the same party.
Malaysia is a PIC/S member market of roughly 34 million people, an English-language regulatory environment, and the practical base from which a product can later move across ASEAN. It is also a market you cannot enter alone: the registration must be held by a locally incorporated company.
This page is the operational overview - the four steps, what your home approval is worth here, and where the route differs depending on which regulator approved your product. If you already know your region, jump straight to it.
The four steps, in order
| # | Step | What it means |
|---|---|---|
| 1 | Product registration | NPRA evaluates the dossier and issues an MAL number. Nothing can be imported or sold before this. |
| 2 | Marketing Authorisation Holder | A locally incorporated entity is named as the holder and carries the ongoing legal obligations. |
| 3 | Import licence | The importing entity needs its own licence; the product must already be registered. |
| 4 | Distribution under GDP | Wholesale and distribution operate under Good Distribution Practice. |
Steps 1 and 2 are where foreign manufacturers most often lose control - usually by letting the commercial partner take the holder role by default. Read why that creates lock-in before you sign anything.
What your home approval is actually worth
NPRA operates reliance routes: if a recognised agency has already approved your product, the Malaysian review can be shortened. Which route you qualify for depends entirely on which agency approved you.
| Reference agency | Region | 60-working-day pilot | General FRP |
|---|---|---|---|
| EMA | Europe | Yes (centralised; decentralised for generics) | Yes |
| US FDA | North America | Yes | Yes |
| Swissmedic | Europe | No | Yes |
| UK MHRA | Europe | No | Yes |
| Health Canada | North America | No | Yes |
| PMDA | Japan | No | Yes |
| TGA | Australia | No | Yes |
NPRA also accepts ASEAN Joint Assessment decisions and WHO prequalification and stringent regulatory authority assessments. Agencies outside this list - including Latin American regulators - do not currently open a reliance route.
Two timelines matter. Under the general Facilitated Registration Pathway, abbreviated review targets 90 working days and verification review 30 working days, with the application filed within three years of the reference approval. Separately, a one-year pilot that started on 2 May 2026 targets 60 working days - but it accepts only US FDA and EMA approvals, and the filing window is about three months from that approval. See the fast-track rules in full.
Where are you entering from?
The registration process is the same for everyone. What changes is your starting position - which reliance route is open, whether your dossier format converts, and how your GMP status is treated.
| Region | Your leading advantage | Page |
|---|---|---|
| Europe | EMA, Swissmedic and MHRA are all recognised. An EMA centralised approval opens the 60-working-day route. | Entering from Europe |
| North America | US FDA opens the 60-working-day route. Health Canada is recognised for the general pathway, not the pilot. | Entering from North America |
| Asia | ACTD is already your dossier format. PMDA is recognised; ASEAN Joint Assessment also applies. | Entering from Asia |
| South America | No reliance route yet. PIC/S participation by some regulators supports the GMP file, subject to NPRA review; the review itself is a full one. | Entering from South America |
Who holds the registration - and why it decides everything
A foreign manufacturer cannot be named as the holder of a Malaysian registration. Someone local must be. In practice there are three options, and they are not equivalent:
| Structure | Control | Speed | Exit risk |
|---|---|---|---|
| Your distributor holds it | Low - the registration sits with your commercial partner | Fast | High - changing partner means a transfer they must consent to |
| Your own Malaysian subsidiary | Full | Slow - incorporation, licensing, staffing | Low |
| An independent MAH (what RHMI does) | High - the holder is not your distributor | Fast | Low - separation of regulatory and commercial roles is contractual |
If your registration is already in the wrong hands, it can be moved: Malaysia has a formal transfer procedure that keeps your MAL number.
What RHMI does
RHMI is not a consultancy that writes you a report. We act as the local structure itself - the holder of the registration, the importer of record, and the coordinator of distribution - so that a foreign manufacturer can operate in Malaysia without incorporating and without handing control to a distributor. See our role in Malaysia and what that covers.
Frequently asked questions
Can a foreign company hold a drug registration in Malaysia?
No. The holder of a Malaysian product registration must be a locally incorporated entity. A foreign manufacturer appoints a local Marketing Authorisation Holder (called the Product Registration Holder, or PRH, in NPRA's own documents), which can be a distributor, a subsidiary, or an independent MAH.
How long does drug registration in Malaysia take?
It depends on the route. Full evaluation is the longest. Under the Facilitated Registration Pathway, abbreviated review targets 90 working days and verification review 30 working days. A pilot that began on 2 May 2026 targets 60 working days for products approved by the US FDA or EMA.
Which regulators does NPRA recognise?
Seven reference agencies: EMA, US FDA, Swissmedic, UK MHRA, Health Canada, PMDA Japan and TGA Australia. NPRA also accepts ASEAN Joint Assessment decisions and WHO prequalification or stringent regulatory authority assessments.
Do I need a distributor and an MAH, or is that the same thing?
They are different roles and they do not have to be the same company. The MAH holds the registration and its legal obligations. The distributor sells and moves the product. Combining them is common and convenient, but it ties your registration to your commercial partner.
You might also find useful
- Drug Registration in Malaysia: Process, Timeline and Requirements
- Marketing Authorisation Holder (MAH) in Malaysia: What It Is and How to Appoint One
- Fast-Track Registration: Register Your FDA/EMA-Approved Drug Faster in Malaysia
- Sources:
- NPRA - New Route under the Facilitated Registration Pathway (FRP), one-year pilot from 2 May 2026: npra.gov.my
- NPRA Drug Registration Guidance Document (DRGD): npra.gov.my (DRGD)
- RAPS - Malaysia's NPRA updates regulatory reliance guide, expands pool of reference agencies: raps.org
- Editorial note: This page is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal or regulatory advice. Timelines, fees and eligibility are administrative details that change; confirm them against NPRA's current guidance before acting. Last reviewed against NPRA guidance: 15 August 2026.